Osteoarthritis, a disease that causes severe joint pain, affects more than 20 million people in the United States. Some drug treatments can help alleviate the pain, but there are no treatments that can reverse or slow the cartilage breakdown associated with the disease.
In an advance that could improve the treatment options available for osteoarthritis, MIT engineers have designed a new material that can administer drugs directly to the cartilage. The material can penetrate deep into the cartilage, delivering drugs that could potentially heal damaged tissue.
“This is a way to get directly to the cells that are experiencing the damage, and introduce different kinds of therapeutics that might change their behavior,” says Paula Hammond, head of MIT’s Department of Chemical Engineering, a member of MIT’s Koch Institute for Integrative Cancer Research, and the senior author of the study.
In a study in rats, the researchers showed that delivering an experimental drug called insulin-like growth factor 1 (IGF-1) with this new material prevented cartilage breakdown much more effectively than injecting the drug into the joint on its own.
Brett Geiger, an MIT graduate student, is the lead author of the paper, which appears in the Nov. 28 issue of Science Translational Medicine. Other authors are Sheryl Wang, an MIT graduate student, Robert Padera, an associate professor of pathology at Brigham and Women’s Hospital, and Alan Grodzinsky, an MIT professor of biological engineering.
Osteoarthritis is a progressive disease that can be caused by a traumatic injury such as tearing a ligament; it can also result from gradual wearing down of cartilage as people age. A smooth connective tissue that protects the joints, cartilage is produced by cells called chondrocytes but is not easily replaced once it is damaged.
Previous studies have shown that IGF-1 can help regenerate cartilage in animals. However, many osteoarthritis drugs that showed promise in animal studies have not performed well in clinical trials.
The MIT team suspected that this was because the drugs were cleared from the joint before they could reach the deep layer of chondrocytes that they were intended to target. To overcome that, they set out to design a material that could penetrate all the way through the cartilage.
The sphere-shaped molecule they came up with contains many branched structures called dendrimers that branch from a central core. The molecule has a positive charge at the tip of each of its branches, which helps it bind to the negatively charged cartilage. Some of those charges can be replaced with a short flexible, water-loving polymer, known as PEG, that can swing around on the surface and partially cover the positive charge. Molecules of IGF-1 are also attached to the surface.
When these particles are injected into a joint, they coat the surface of the cartilage and then begin diffusing through it. This is easier for them to do than it is for free IGF-1 because the spheres’ positive charges allow them to bind to cartilage and prevent them from being washed away. The charged molecules do not adhere permanently, however. Thanks to the flexible PEG chains on the surface that cover and uncover charge as they move, the molecules can briefly detach from cartilage, enabling them to move deeper into the tissue.
“We found an optimal charge range so that the material can both bind the tissue and unbind for further diffusion, and not be so strong that it just gets stuck at the surface,” Geiger says.
Once the particles reach the chondrocytes, the IGF-1 molecules bind to receptors on the cell surfaces and stimulate the cells to start producing proteoglycans, the building blocks of cartilage and other connective tissues. The IGF-1 also promotes cell growth and prevents cell death.
When the researchers injected the particles into the knee joints of rats, they found that the material had a half-life of about four days, which is 10 times longer than IGF-1 injected on its own. The drug concentration in the joints remained high enough to have a therapeutic effect for about 30 days. If this holds true for humans, patients could benefit greatly from joint injections — which can only be given monthly or biweekly — the researchers say.
In the animal studies, the researchers found that cartilage in injured joints treated with the nanoparticle-drug combination was far less damaged than cartilage in untreated joints or joints treated with IGF-1 alone. The joints also showed reductions in joint inflammation and bone spur formation.
“This is an important proof-of-concept that builds on the recent advances in the identification of anabolic growth factors with clinical promise (such as IGF-1), with promising disease-modifying results in a clinically relevant model. Delivery of growth factors using nanoparticles in a manner that sustains and improves treatments for osteoarthritis is a significant step for nanomedicines,” says Kannan Rangaramanujam, a professor of ophthalmology and co-director of the Center for Nanomedicine at Johns Hopkins School of Medicine, who was not involved in the research.
Cartilage in rat joints is about 100 microns thick, but the researchers also showed that their particles could penetrate chunks of cartilage up to 1 millimeter — the thickness of cartilage in a human joint.
“That is a very hard thing to do. Drugs typically will get cleared before they are able to move through much of the cartilage,” Geiger says. “When you start to think about translating this technology from studies in rats to larger animals and someday humans, the ability of this technology to succeed depends on its ability to work in thicker cartilage.”
The researchers began developing this material as a way to treat osteoarthritis that arises after traumatic injury, but they believe it could also be adapted to treat age-related osteoarthritis. They now plan to explore the possibility of delivering different types of drugs, such as other growth factors, drugs that block inflammatory cytokines, and nucleic acids such as DNA and RNA.
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
- This Is What Sex Is Like When You Also Have a Chronic Illnesson April 6, 2020 at 8:01 am
"I felt really diminished as a man—as a person." Jack, a 58-year-old audiobook producer and narrator in New York who suffers from fibromyalgia and osteoarthritis, also struggled with feelings of ...
- 7 Rheumatoid Arthritis Symptoms Every Woman Should Know Abouton April 6, 2020 at 7:30 am
This is normal — RA typically affects people between the ages of 30 and 60. I grew up constantly hearing about arthritis (or “Arthur Itis” as my grandmother — who had osteoarthritis — would say) and ...
- Osteoarthritis is not related to osteoporosison April 5, 2020 at 10:00 pm
Dear Dr. Roach • After taking prednisone for several years I suffered a fracture of the tibia. My doctors took me off the prednisone and prescribed generic Fosamax. My last ...
- Week In Review: Signs Of Life After Coronavirus - China Biopharma Scores $721 Million In Dealson April 5, 2020 at 9:02 am
Ping An announced a $311 million agreement with Japan's Shionogi to develop new drugs for infectious diseases and CNS needs based on Ping An's lifestyle data. H ...
- Tanezumab: A Win as Last-Ditch Osteoarthritis Txon April 3, 2020 at 8:21 am
A phase III study of the nerve growth factor and monoclonal antibody tanezumab showed positive results in a refractory patient population with knee or hip osteoarthritis (OA) -- good enough that this ...
- Osteoarthritis of the knee in professional football players: IIAC position paper 44on April 3, 2020 at 2:53 am
This position paper updates an earlier review by the Council into Sporting Injuries published in 2005. A comprehensive review of the recent published literature relating to osteoarthritis (OA) in ...
- Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in Chinaon April 1, 2020 at 12:50 am
TOKYO, Apr 1, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing ...
- The Global Osteoarthritis Pain Drug Market is...on March 31, 2020 at 7:38 am
Reportlinker.com announces the release of the report "Global Osteoarthritis Pain Drug Market - Premium Insight, ...
- PAINWeek 2020 Welcomes Osteoarthritis Research Society Internationalon March 25, 2020 at 3:05 am
PAINWeek is pleased to announce that the Osteoarthritis Research Society International (OARSI)—for the first time—will present a full day track at the PAINWeek National Conference on Tuesday, ...
via Bing News